CD19 and CD37 proteins are highly expressed in B-cell lymphoma and have been successfully targeted with different monotherapies, including chimeric antigen receptor (CAR)-T cell therapy. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.